6 completed, 4 withdrawn, 3 unknown, 2 recruiting. 19 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 19 | Completed 6, Withdrawn 4, Unknown 3, Recruiting 2, Terminated 2, Active not recruiting 1, Suspended 1 |
Follow Chlorthalidone: new trials by email Literature Review of Chlorthalidone trials Research Report on Chlorthalidone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CaOx Stone Prevention Chlorthalidone, Low oxalate diet - Kidney Stones | Phase 4 | Recruiting | Icahn School of Medicine at Mount Sinai | 80 | 2025-10-23 | 2026-08-14 |
| Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg, Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg - Essential Hypertension | Phase 4 | Active not recruiting | Yuhan Corporation | 198 | 2023-10-18 | 2026-02-13 |
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension Eplerenone, Chlorthalidone, Potassium - Hypertension, Left Ventricular Hypertrophy | Phase 4 | Recruiting | Brigham and Women's Hospital | 75 | 2023-08-25 | 2026-04-06 |
| Diuretic Use in Hemodialysis Patients With Residual Renal Function Furosemide, Chlorthalidone - End Stage Renal Disease on Dialysis | Phase 4 | Terminated | University of Alberta | 2 | 2023-05-29 | 2026-05-08 |
| Diuretics and Volume Overload in Early CKD Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide) - Chronic Kidney Disease, Hypertension | Phase 4 | Completed | VA Office of Research and Development | 49 | 2023-02-01 | 2026-09-21 |
| Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN) Amlodipine Besylate, Chlorthalidone - High Blood Pressure, Liver Transplant | Phase 4 | Withdrawn | Northwestern University | 2022-07-12 | 2023-10-13 | |
| Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment UNa measurement after intravenous loop diuretic bolus, Intravenous acetazolamide 500 mg OD, Intravenous bumetanide TID - Acute Heart Failure, Diuretics Drug Reactions | Phase 4 | Completed | Vrije Universiteit Brussel | 107 | 2022-06-12 | 2026-09-11 |
| Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity Eplerenone, Chlorthalidone with potassium chloride - Metabolic Syndrome, Hypertension | Phase 4 | Completed | Brigham and Women's Hospital | 79 | 2020-12-01 | 2026-09-15 |
| Coronavirus (COVID-19) ACEi/ARB Investigation Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor - Hypertension, COVID-19 | Phase 4 | Suspended | National University of Ireland, Galway, Ireland | 2414 | 2020-04-30 | 2020-06-30 |
| Comparison of Optimal Hypertension Regimens Amlodipine, Lisinopril, Amiloride - Hypertension | Phase 4 | Completed | Cambridge University Hospitals NHS Foundation Trust | 940 | 2016-11-01 | 2025-09-05 |
| EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network Chlorthalidone, Hydrochlorothiazide - Hypertension | Phase 4 | Withdrawn | Johns Hopkins University | 2016-08-01 | 2017-08-18 | |
| S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension S-amlodipine 2.5mg + Chlorthalidone 25mg, S-amlodipine 2.5mg + Telmisartan 40mg - Essential Hypertension | Phase 4 | Unknown | Seoul National University Bundang Hospital | 170 | 2015-12-02 | 2017-07-21 |
| Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD Spironolactone, Chlortalidone - Renal Insufficiency, Chronic, Cardio-Renal Syndrome | Phase 4 | Unknown | University Hospital Birmingham | 154 | 2014-06-01 | 2018-01-19 |
| Chlorthalidone and HCTZ Impacts on Platelet Activation Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Aspirin 81 mg - Hypertension | Phase 4 | Unknown | Creighton University | 30 | 2014-03-01 | 2015-12-14 |
| The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone Chlorthalidone - Resistant Hypertension in Kidney Transplant Patients | Phase 4 | Withdrawn | Virginia Commonwealth University | 2013-07-01 | 2017-06-15 | |
| Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Placebo - Hypertension | Phase 4 | Withdrawn | Creighton University | 2013-03-01 | 2015-03-25 | |
| A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD Chlorthalidone - Chronic Kidney Disease, Poorly-Controlled Hypertension | Phase 4 | Completed | Indiana University | 14 | 2012-08-01 | 2016-06-13 |
| Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes Valturna, Amlodipine, Chlorthalidone - Hypertension, Stage 2 Hypertension | Phase 4 | Terminated | Novartis Pharmaceuticals | 975 | 2011-05-01 | 2013-03-21 |
| Pharmacogenomic Evaluation of Antihypertensive Responses 2 Metoprolol, Chlorthalidone - Hypertension | Phase 4 | Completed | University of Florida | 839 | 2010-08-01 | 2018-04-06 |
Hypertension (12) · Renal Insufficiency, Chronic (3) · Essential Hypertension (2) · COVID-19 (1) · Cardio-Renal Syndrome (1) · Cardiovascular Diseases (1) · Coronavirus Infections (1) · Diabetes Mellitus (1) · Edema (1) · Hypertrophy, Left Ventricular (1) · Kidney Calculi (1) · Kidney Diseases (1) · Metabolic Syndrome (1) · Nephrolithiasis (1) · Obesity (1)
Brigham and Women's Hospital (2) · Creighton University (2) · Cambridge University Hospitals NHS Foundation Trust (1) · Icahn School of Medicine at Mount Sinai (1) · Indiana University (1) · Johns Hopkins University (1) · National University of Ireland, Galway, Ireland (1) · Northwestern University (1) · Novartis Pharmaceuticals (1) · Seoul National University Bundang Hospital (1) · University Hospital Birmingham (1) · University of Alberta (1) · University of Florida (1) · VA Office of Research and Development (1) · Virginia Commonwealth University (1)
United States (12) · South Korea (2) · United Kingdom (2) · Belgium (1) · Canada (1) · Ireland (1) · Puerto Rico (1)
Ahmed Aboeata, MBBCh (1) · Anand Vaidya, MD (1) · Branko Braam, MD/Ph.D. (1) · Dempsey Hughes, MD (1) · Frederik H Verbrugge, M.D.; Ph.D.; M.Sc. (1) · Gail K Adler, MD, PhD (1) · Gaurav Gupta, MD (1) · Gemma Slinn (1) · Ian Wilkinson (1) · John William McEvoy, MBBCh MHS (1) · Julie A Johnson, PharmD (1) · Khalid Bashir, MD (1) · Lucile P Gregg, MD MS (1) · Mantu Gupta, MD (1)
PMID 11904577, PMID 28115488, PMID 29523524, PMID 29925376, PMID 29925421, PMID 30092411, PMID 30753254, PMID 31791376, PMID 36067089, PMID 38353215, PMID 38447632, PMID 38747311, PMID 39082471
1IK2CX002368-01A1 (1), R56HL155093 (1), U01GM074492 (1)